ALZpath files for $10.4M Series A to scale blood-based Alzheimer's tests
What's the deal? ALZpathDealroom has a profile for this one. Try Dealroom →, a diagnostics startup, filed a notice with the US Securities and Exchange Commission to raise $10,411,219 in a Series A round. The filing, dated August 2026, reports an exempt offering of securities under Regulation D.
What's the endgame? Founded in 2020, ALZpath develops blood-based biomarkers for detecting Alzheimer's disease. Its focus is a proprietary pTau217 antibody used to build blood tests aimed at earlier, more accessible diagnosis.
Why now? The company wants to move Alzheimer's detection out of specialized clinics and into routine care. It says its antibody is already used by diagnostic firms to create tests that detect the disease "quickly, accurately, and at scale."
The signal: The round sits in the 27th percentile by size — modest for a Series A. But the effort reflects a broader push to replace late, invasive Alzheimer's diagnosis with earlier blood-based testing.
Read more: intelligence360.news
Image credit: exit78
